Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep-deprived subjects

Human Psychopharmacology

Volumn 15, Issue 3, 2000, Pages 153-170

  Patat, Alain ^a,f   Rosenzweig, Pierre ^b   Enslen, Marc ^c   Trocherie, Suzanne ^d   Miget, Nathalie ^b   Bozon, Marie Christine ^c   Allain, HERVÉ ^e   Gandon, Jean Marc ^a  

^a Biotrial SA   (France)

^b SANOFI   (France)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f Wyeth Ayerst Research European CR and D Department   (France)

Author keywords

Caffeine; EEG; Humans; Performance tasks; Sleep deprivation

Indexed keywords

CAFFEINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ADULT; ALERTNESS; ALPHA RHYTHM; ANXIETY; ARTICLE; BETA RHYTHM; BODY EQUILIBRIUM; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DELTA RHYTHM; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; EYE TRACKING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SIDE EFFECT; SLEEP DEPRIVATION; SLOW RELEASE FORMULATION; SOMNOLENCE; THETA RHYTHM; TREMOR;

EID: 0034103192     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(200004)15:3<153::AID-HUP154>3.0.CO;2-C     Document Type: Article

References (93)

1. Barone JJ, Roberts H. 1984. Human consumption of caffeine. In Caffeine: Perspectives from Recent Research, Dews PB (ed.). Springer: New York; 57-73.
2. Barone JJ, Roberts HR. 1996. Caffeine consumption. Food Chem Toxicol 34: 119-129.
3. Bartel P, Delport R, Lotz B, Ubbink J, Becker P. 1991. Effects of single and repeated doses of theophylline on aspects of performance, electrophysiology and subjective assessments in healthy human subjects. Psychopharmacology 106: 90-96.
4. Batejat D, Lagarde D. 1992. Circadian rhythm and sleep deprivation: effects on psychomotor performance. Med Sci Res 20: 167-168.
5. Battig K, Welzl H. 1993. Psychopharmacological profile of caffeine. In Caffeine Coffee and Health, Garrattini S (ed.). Raven Press: New York; 213-253.
6. Benowitz NL. 1990. Clinical pharmacology of caffeine. Ann Rev Med 41: 227-288.
7. Bensimon G, Benoit D, Lacomblez L, Weiller E, Warot D, Weil JS, Puech AJ. 1991. Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep deprivation in 12 healthy volunteers. Eur Psychiat 6: 93-97.
8. Brockwell NT, Eikelboom R, Beninger RJ. 1991. Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 38: 513-517.
9. Bruce M, Scott N, Lader M, Marks V. 1986. The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects. Br J Clin Pharmacol 22: 81-87.
10. Bruce M, Scott N, Shine P, Lader M. 1992. Anxiogenic effects of caffeine in patients with anxiety disorders. Arch Gen Psychiat 49: 867-869.
11. Chait LD. 1992. Factors influencing the subjective response to caffeine. Behav Pharmacol 3: 219-228.
12. Chait LD, Griffiths PR. 1983. Effects of caffeine on cigarette smoking and subjective response. Clin Pharmacol Therapeut 34: 612-622.
13. Charney DS, Galloway MP, Heninger GR. 1984. The effects of caffeine on plasma MHPG, subjective anxiety, autonomic symptoms and blood pressure in healthy humans. Life Sci 35: 135-144.
14. Charney DS, Heninger GR, Jatlow PI. 1985. Increased aniogenic effects of caffeine in panic disorders. Arch Gen Psychiat 42: 233-243.
15. Clubley M, Bye CE, Henson TA, Peck AW, Riddington CJ. 1979. Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity. Br J Clin Pharmacol 7: 157-163.
16. Daly JW. 1982. Adenosine receptors: targets for future drugs. J Med Chem 25: 197-207.
17. Daly JW. 1993. Mechanism of action of caffeine. In: Caffeine, Coffee and Health, Garattini S. (ed.). Raven Press: New York; 97-150.
18. Dews PB. 1984. Behavioural effects of caffeine. In: Caffeine, Dews PB (ed.). Springer: New York; 86-103.
19. Dimpfel W, Schober F, Spuler M. 1993. The influence of caffeine on human EEG under resting conditions and during mental loads. Clin Invest 71: 197-207.
20. Doireau P, Batejat D, Chauffard F, Enslen M, Tachon P, Pradella S, Lagarde D. 1997. Cognitive performance during a 64 hours sleep deprivation: interest of a slow release caffeine. NATO-RTA-AMP meeting (29 Sept-3 Oct 1997) Rotterdam.
21. Etevenon P, Peron-Magnan P, Boulenger JP, Tortrat D, Guillot S, Toussaint M, Gueguen B, Deniker P, Zarifian E. 1986. EEG cartography profile of caffeine in normals. Clin Neuropharmacol 9: 538-540.
22. Etevenon P, Peron-Magnan P, Guillou S, Toussaint M, Gueguen B, Deniker P, Loo H, Zarifian E. 1989. A pharmacological model of local cerebral activation: EEG cartography of caffeine effects in normals. In: Brain imaging: applications in psychiatry, Andreasen NC (ed.). American Psychiatric Press: Washington, DC; 171-180.
23. File SE, Bond AJ, Lister RG. 1982. Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol 2(2): 102-106.
24. Frewer LJ, Lader M. 1991. The effects of caffeine on two computerized tests of attention and vigilance. Human Psychopharmacol 6: 119-128.
25. Gandon JM, Le Coz F, Enslen F, Chauffard P, Tachon P, Allain H, Patat A. 1996. Determination of the maximal tolerated dose of a new acute oral caffeine formulation in healthy volunteers. Clin Pharmacol Therapeut 59: 179.
26. Ghoneim MM, Hinrichs HV, Chiang CK, Loke WH. 1986. Pharmacokinetic and pharmacodynamic interactions between caffeine and diazepam. J Clin Psychopharmacol 6: 75-80.
27. Gilbert RM. 1984. Caffeine consumption. In: The methylxanthine beverages and foods: chemistry, composition and health effects, Spiller GA (ed.). Liss: New York; 185-213.
28. Glenville M, Broughton R, Wing AM, Wilkinson RT. 1978. Effects of sleep deprivation on short duration performance measures compared to the Wilkinson Auditory Vigilance Task. Sleep 11(2): 169-176.
29. Goldstein L, Muphee HB, Pfeiffer CC. 1963. Quantitative electroencephalography in man as a measure of CNS stimulation. Ann NY Acad Sci 107: 1045-1056.
30. Gorissen M, Tielemans M, Coenen A. 1997. Alertness and memory after sleep deprivation and diazepam intake. J Psychopharmacol 11(3): 233-239.
31. Griffiths RR, Woodson PP. 1988a. Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacol 94: 437-451.
32. Griffiths RR, Woodson PP. 1988b. Reinforcing effects of caffeine in humans. J Pharmacol Exp Therapeut 246: 21-29.
33. Griffiths RR, Woodson PP. 1988c. Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 29: 419-427.
34. Griffiths RR, Bigelow GE, Liebson IA. 1989. Reinforcing effects of caffeine in coffee and capsules. J Exp Analyt Behav 52: 127-140.
35. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B, Woodson PP. 1990. Low-dose caffeine discrimination in humans. J Pharmacol Exp Therapeut 252: 970-978.
36. Hasenfratz M, Bättig K. 1992. Action profiles of smoking and caffeine: Stroop effect, EEG. and peripheral physiology. Pharmacol Biochem Behav 42: 155-161.
37. Hasenfratz M, Bättig K. 1994. Acute dose-effect relationships of caffeine and mental performance, EEG, cardiovascular and subjective parameters. Psychopharmacol 114: 281-287.
38. Heischman SJ, Henningfield JE. 1991. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacol 103: 436-442.
39. Heischman SJ, Henningfield JE. 1992. Stimulus functions of caffeine in humans: relation to dependence potential. Neurosci Biobehav Rev 16: 273-287.
40. Herrmann WM. 1982. Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In EEG in Drug Research, Hermann W. (ed.). Gustav Fischer Verlag: Stuttgart; 249-351.
41. Hoddes E, Zarcone V, Smythe H, Philips R, Dement WC. 1973. Stanford sleepiness scale. Quantification of sleepiness: a new approach. Psychophysiol 10: 431-436.
42. Holzman S. 1990. Caffeine as a model drug of abuse. Trends Pharmacol Sci 11: 355-356.
43. Horne JA, Pettitt AN. 1985. High incentive effects on vigilance performance during 72 hours of total sleep deprivation. Acta Psychol 58: 123-139.
44. Jarvis MJC. 1993. Does caffeine intake enhance absolute levels of cognitive performance? Psychopharmacol 110: 45-52.
45. Johnson LC, Spinweber CL, Gomez SA. 1990a. Benzodiazepines and caffeine: effect on daytime sleepiness, performance and mood. Psychopharmacol 101: 160-167.
46. Johnson LC, Spinweber CL, Gomez SA, Matteson LT. 1990b. Daytime sleepiness, performance, mood, nocturnal sleep: the effect of benzodiazepine and caffeine on their relationship. Sleep 13(2): 121-135.
47. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. 1992. Caffeine-induced behavioural stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacol 6: 145-153.
48. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE. Cotreau MM, Harmatz JS, Shader RI. 1997. Dose-dependent pharmacokinetic and psychomotor effects of caffeine in humans. J Clin Pharmacol 37: 693-703.
49. Kapteyn TS, Bles W, Njiokiktjein CJ, Kodde L, Massen CH, Mol JMF. 1983. Standardisation in platform stabilometry being part of posturography. Agressologie 24: 321-326.
50. Kjelberg A. 1977a. Sleep deprivation and some aspects of performance. II. Lapses and other attentional effects. Waking and Sleeping 1: 145-148.
51. Kjelberg A. 1977b. Sleep deprivation and some aspects of performance. III. Motivation, Comment and Conclusions. Waking and Sleeping 1: 149-153.
52. Koelega HS. 1993. Stimulant drugs and vigilance performance: a review. Psychopharmacol 111: 1-16.
53. Koslowsky M, Babkoff H. 1992. Meta-analysis of the relationship between total sleep deprivation and performance. Chronobiol Int 9(2): 132-136.
54. Lader MH, Bruce MS. 1989. The human psychopharmacology of the methylxanthines. In: Human Psychopharmacology: Measures and Methods, Hindmarch I, Stonier PD (eds). John Wiley: Chichester; 179-200.
55. Lagarde D, Batejat D, VAN Beers P, Sarafian D, Pradella S. 1995. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundamental Clin Pharmacol 9: 271-279.
56. Lagarde D, Batejat D, Enslen M, Chauffard F, Tachon P. 1996. Interest of a new time release caffeine to maintain psychomotor performance. J Sleep Res 5, 1: 115.
57. Liebermann HR, Wurtman RJ, Emde GG, Roberts C, Coviella ILG. 1987a. The effects of low doses of caffeine on human performance and mood. Psychopharmacol 92: 308-312.
58. Liebermann FR, Wurtman RJ, Emde GC, Coviella ILG. 1987b. The effects of caffeine and aspirin on mood and performance. J Clin Psychopharmacol 7: 315-320.
59. Loke WH. 1988. Effects of caffeine on mood and memory. Physiol Behav 44: 367-372.
60. Loke WH, Hinrichs JV, Ghoneim MM. 1985. Caffeine and diazepam: separate and combined effects on mood, memory, and psychomotor performance. Psychopharmacol 87: 344-350.
61. Lorist MM, Snel J, Kok A. 1994. Influence of caffeine on information processing stages in well rested and fatigued subjects. Psychopharmacol 113: 411-421.
62. Lumley M, Roehrs T, Asker D, Zorick F, Roth T. 1987. Ethanol and caffeine effects on daytime sleepiness/alertness. Sleep 10: 306-312.
63. Marks M, Folkard S. 1984. Diurnal rhythms in cognitive performance. In: Psychology Survey, Vol. 5, Nicholson J, Beloff H. (eds). British Psychological Society: Leicester; 63-94.
64. Mattila MJ, Palva E, Savolainen K. 1982. Caffeine antagonizes diazepam effects in man. Med Biol 60: 121-123.
65. Mattila M, Seppala T, Mattila MJ. 1988. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int J Clin Pharmacol 3: 215-229.
66. McClelland GR. 1989. Body sway and the effects of psychoactive drugs - a review. Human Psychopharmacol 4: 3-14.
67. Mikulincer M, Babkoff H, Capsy T, Sing H. 1989. The effects of 72 hours of sleep loss on psychological variables. Br J Psychol 80: 145-162.
68. Nehlig A, Daval JL, Debry G. 1992. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 17: 139-170.
69. Newhouse PA, Belenkyg, Thomas M, Thorne D, Sing HC, Fertig J. 1989. The effects on d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation. Neuropsychopharmacol 2: 153-164.
70. Patat A, Cercle M, Trocherie S, Peytavin G, Potin C, Allain H, Gandon JM. 1996. Lack of amphetamine-like effects after administration of mefenorex in normal young subjects. Human Psychopharmacol 2: 321-335.
71. Penetar D, Mccann U, Thorne D, Kamimori G, Galinski C, Sing H, Thomas M, Belenky G. 1993. Caffeine reversal of sleep deprivation effects on alertness and mood. Psychopharmacol 112: 359-365.
72. Rappelsberger P, Pockberger H, Petsche H. 1986. Computer aided EEG analysis - evaluation of changes during cognitive processes and topographic mapping. EDV Med Biol 17: 45-53.
73. Roache JD, Griffiths RR. 1987. Interactions of diazepam and caffeine: behavioural and subjective dose effects in humans. Pharmacol Biochem Behav 26: 801-812.
74. Rosenthal L, Roehrs T, Zwyghuizen-Doorenbos A, Plath D, Roth T. 1991. Alerting effects of caffeine after normal and restricted sleep. Neuropsychopharmacol 4(2): 103-108.
75. Rosvold ME, Mirsky AF, Sarason I, Bransome ER Jr, Beck LH. 1956. A continuous performance test for brain damage. J Consult Psychol 20(5): 343-350.
76. Saletu B. 1987. The use of pharmaco-EEG in drug profiling. In: Human Psychopharmacology: Measures and Methods, Hindmarch I, Stonier PD. (eds). John Wiley and Sons: Chichester; 177-200.
77. Saletu B, Anderer P, Kinsberger K, Grunberger J. 1987. Topographic brain mapping of EEG in neuropsychopharmacology. Clinical applications (pharmaco EEG imaging). Methods Findings Exp Clin Pharmacol 9: 385-408.
78. Sawyer DA, Julia HL, Turin AC. 1982. Caffeine and human behavior: arousal, anxiety and performance effects. J Behav Med 5(4): 415-439.
79. Sawynok J. 1995. Pharmacological rationale for the clinical use of caffeine. Drugs 49: 37-50.
80. Schreiber GB, Maffeo CE, Robins M. 1988. Measurement of coffee and caffeine intake: implications for epidemiological research. Prevent Med 17: 280-294.
81. Sicard B, Perault MC, Enslen M, Chauffard F, Vandel B, Tachon P. 1996. The effects of 600 mg of slow release caffeine on mood and alertness. Aviation, Space Environ Med 67(9): 859-862.
82. Silverman K, Evans SM, Strain EC, Griffiths RR. 1992. Withdrawal syndrome after the double-blind cessation of caffeine consumption. New England J Med 327: 1109-1114.
83. Smulders FT, Kenemans JL, Jonkman LM, Kok A. 1997. The effects of sleep loss on task performance and the electroencephalogram in young and elderly subjects. Biol Psychol 45: 217-239.
84. Snyder SH, Katims JJ, Annau Z, Bruns RF, Daly JW. 1981. Adenosine receptors and behavioral actions of methylxanthines. Proc Nat Acad Sci USA 78: 3260-3264.
85. Stern KN, Chait LD, Johanson CE. 1989. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacol 98: 81-88.
86. Stroop JR. 1935. Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-662.
87. Uhde TW, Boulenger JP, Jimerson DC. Post RM. 1984. Caffeine: relationship to human anxiety, plasma MHPG, and cortisol. Psychopharmacol Bull 20: 426-430.
88. Van Steveninck AL, Van Berckel BNM, Schoemaker HC, Breimer DD, Cohen AF. 1993. Sensitivity of CNS performance tests to the effects of sleep deprivation. Br J Clin Pharmacol 35(5): 551P.
89. Walsh JK, Muehlbach MJ, Humm TM Dickins QS, Sugerman JL, Schweitzer PK. 1990. Effects of caffeine on physiological sleep tendency and ability to sustain wakefulness at night. Psychopharmacol 101: 271-273.
90. Warot D, Corruble E, Payan C, Weil JS, Puech AJ. 1993. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. Eur Psychiat 8: 201-208.
91. Weiss B, Laties VG. 1962. Enhancement of human performance by caffeine and the amphetamines. Pharmacol Rev 14: 1-36.
92. Wimmer F, Hoffmann RF, Bonato RA, Moffitt AR. 1992. The effects of sleep deprivation on divergent thinking and attention processes. J Sleep Res 1: 223-230.
93. Zwyghuizen-Doorenbos A, Roehrs TA, Lipschuts L, Timms V, Roth T. 1990. Effects of caffeine on alertness. Psychopharmacol 100: 36-39.